Recruiting
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis - IM014-029
Updated: 14 September, 2021 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: Sub-study for Systemic Lupus Erythematosus (SLE) - Active SLE as defined by the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) classification - Diagnosed with SLE more than 24 weeks before screening visit Sub-study for primary Sjögren's Syndrome (pSS) - Moderate to severe pSS, meeting ACR-EULAR classification criteria Sub-study for active Rheumatoid Arthritis (RA) - Moderate to severe adult-onset RA - ACR global functional status class I to III Women and men must agree to follow instructions for methods of contraception. Exclusion Criteria: Sub-study for Systemic Lupus Erythematosus - Certain other autoimmune diseases and overlap syndromes Sub-study for primary Sjögren's Syndrome - Certain other immune-mediated diseases, active fibromyalgia, or other medical conditions Sub-study for Rheumatoid Arthritis (RA) - Diagnosis with juvenile arthritis or idiopathic arthritis before age 16 For all sub-studies: - History of any significant drug allergy - Active infection, significant concurrent medical condition, or clinically significant abnormalities Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
